ClinicalTrials.gg
Not yet recruitingNCT07938905Updated Nov 16, 2026

Liposomal Bupivacaine Nerve Block for Knee Replacement Pain: Added Value and Optimization

An interventional study of Liposomal Bupivacaine (EXPAREL®)/Bupivacaine and Ultrasound-Guided Adductor Canal Block in Osteoarthritis, Knee; Postoperative Pain, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Not yet recruiting. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing Liposomal Bupivacaine in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Liposomal Bupivacaine · Osteoarthritis.

Started
2026
the only one that year
No phase
5 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Among the 10 studies testing Liposomal Bupivacaine in Osteoarthritis, this one is the only one that started in 2026, is one of 5 with no phase, and was the 10th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 10 studies testing Liposomal Bupivacaine in Osteoarthritis is open now.

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Liposomal Bupivacaine in Osteoarthritis, or all of them as a file.
02

Study summary

Background Total knee arthroplasty (TKA) effectively relieves end-stage knee osteoarthritis, yet moderate-to-severe postoperative pain substantially compromises early functional exercise and rehabilitation. Liposomal bupivacaine, with a duration of action of up to 72 hours, offers a means of extending the postoperative pain-free window. However, previous studies have been limited by non-standardized background analgesia, absent head-to-head comparison of block targets, reliance on short-term resting pain scores, and inadequate blinding. Consequently, both the added value of liposomal bupivacaine nerve block on top of intravenous patient-controlled analgesia (IV-PCA) plus local infiltration analgesia (LIA), and the optimal block target, remain unresolved.

Objective To determine the analgesic added value of a single-shot liposomal bupivacaine targeted nerve block superimposed on standardized multimodal analgesia, and to compare the analgesic and functional recovery profiles of alternative block targets, thereby informing an optimized perioperative analgesic strategy.

Methods In this prospective, randomized, double-blind, three-arm controlled trial, 〔n〕 patients scheduled for unilateral TKA will be randomized to 〔arms to be confirmed: (1) background analgesia alone; (2) adductor canal block (ACB); (3) ACB combined with IPACK block〕. All patients receive standardized background analgesia comprising IV-PCA and intraoperative LIA. The primary endpoint is movement-evoked pain numeric rating scale (NRS) score at 〔24〕 h postoperatively. Secondary endpoints include resting pain scores, cumulative opioid consumption, time to first ambulation, knee range of motion, incidence of postoperative nausea and vomiting (PONV), and length of hospital stay.

03

Conditions studied

  • Osteoarthritis, Knee; Postoperative Pain
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Age 65 to 85 years at the time of surgery. Scheduled for elective unilateral total knee arthroplasty for end-stage knee osteoarthritis.

≥18.5 and \<25 kg/m². (ASA) physical status I to III. Written obtained from the patient before any study procedure. Able to understand and use the numeric rating scale (NRS) for pain and to complete the quality-of-recovery questionnaire.

Exclusion Criteria:Refusal to participate, or withdrawal of consent at any time.

Known allergy or to bupivacaine, ropivacaine, oxycodone, or other study-related medications.

Infection at or near the planned puncture sites, or systemic infection. Coagulopathy, or current anticoagulant/antiplatelet therapy that precludes deep peripheral nerve block.

Pre-existing peripheral neuropathy, motor or sensory deficit in the operated limb, or other to neuraxial/peripheral block.

Chronic opioid use (≥3 months) or a history of opioid dependence. Severe hepatic or renal impairment (e.g. \<30 mL/min/1.73 m², or class B/C).

Severe cardiopulmonary disease (e.g. unstable angina, class III-IV heart failure, severe ), or ASA physical status IV or higher.

Preoperative knee flexion contracture >15° or varus deformity >15°, or previous surgery on the index knee (including prior arthroplasty).

Cognitive impairment, psychiatric disorder, illiteracy, or language barrier that would prevent valid pain and recovery assessment.

Participation in another interventional trial within 30 days. Vulnerable populations: minors, pregnant or lactating women, prisoners, and persons unable to give voluntary informed consent.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Adductor Canal Block (ACB)

    Drug: Liposomal Bupivacaine (EXPAREL®)/Bupivacaine · Procedure: Ultrasound-Guided Adductor Canal Block

  • Experimental
    ACB Plus IPACK Block

    Drug: Liposomal Bupivacaine (EXPAREL®)/Bupivacaine · Procedure: Ultrasound-Guided Adductor Canal Block · Procedure: Ultrasound-Guided IPACK Block

  • No intervention
    Background Analgesia Alone

Interventions

  • DrugLiposomal Bupivacaine (EXPAREL®)/Bupivacaine

    Drug page: Liposomal Bupivacaine

    Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

  • ProcedureUltrasound-Guided Adductor Canal Block

    A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

  • ProcedureUltrasound-Guided IPACK Block

    A single-shot IPACK (interspace between the popliteal artery and the capsule of the posterior knee) block is performed with the patient supine and the knee flexed approximately 30 degrees. A high-frequency linear transducer is positioned in the popliteal crease with the popliteal artery identified in short axis, and a 22-gauge needle is advanced in-plane from medial to lateral until the tip lies in the fascial plane between the popliteal artery and the posterior capsule of the knee. After negative aspiration, the study solution is injected with real-time visualization of spread along this plane, without puncturing the popliteal vessels.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Achieving Pain-Free Rehabilitation Within 72 Hours After Surgery (Composite)

    Composite primary endpoint, defined as the proportion of patients meeting all three of the following criteria within 72 hours after surgery: (1) adequate pain control-numeric rating scale (NRS) score ≤3 for movement-evoked pain during 45° knee flexion at 24, 48, and 72 hours postoperatively; (2) functional progress-ability to walk ≥20 m with assistance within 72 hours; and (3) opioid sparing-cumulative intravenous oxycodone consumption ≤40 mg (or morphine-equivalent dose) from 0 to 72 hours postoperatively.

    Time frame: 72 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 576 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 24 months is close to that.

Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938905
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion